ArticleQuantitative imaging in medicine and surgery2025
Characteristics of pulmonary lymphoma on baseline
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Localized extranodal lymphoma is generally associated with a more favorable prognosis, whereas systemic lymphomas with extranodal involvement tend to indicate poorer outcomes. The lungs are a common site of invasion, and pulmonary lymphoma may exhibit a diversity of imaging manifestations, which can lead to diagnostic challenges. Therefore, this study aimed to comprehensively characterize the imaging characteristics of pulmonary lymphoma and its subtypes and evaluate their potential for predicting treatment response. Methods: Three observers retrospectively reviewed positron emission tomography/computed tomography (PET/CT) images of patients with lymphoma and recorded the characteristics of the pulmonary lesions. Statistical analyses included Spearman correlation coefficient analysis, the Chi-squared test, and the Fisher's exact test. Results: A total of 136 cases (66 males and 70 females; mean age 54.84±16.66 years) were included. All cases of primary pulmonary lymphoma (PPL) were non-Hodgkin lymphoma (NHL), with mucosa-associated lymphoid tissue (MALT) lymphoma accounting for 88.57%. Diffuse large B-cell lymphoma (DLBCL) was the main subtype in secondary pulmonary lymphoma (SPL), accounting for 50.50%. PPLs typically appeared as consolidations (68.57%) with air bronchograms (62.86%). In contrast, SPL lesions frequently manifested as nodules (76.24%) with homogeneous metabolic distribution (77.23%) and increased metabolic activity in the hilar lymph node (77.23%). Statistical distinctions between PPL and SPL were observed related to lesion size, hilar lymph node involvement, presence of consolidation and air bronchogram signs, metabolic patterns, and target-to-background ratios (TBRs) (P<0.05). Baseline nodular or consolidated lesions and fludeoxyglucose (FDG) distribution patterns were correlated with posttherapy Deauville 5-point scale (5-PS) (P<0.05), although causality could not be inferred. Pleural involvement in PPL was correlated with more favorable treatment response (P=0.001), while the baseline target-to-mediastinal blood pool ratio (TBR Conclusions: PPLs and SPLs demonstrate distinct albeit nonspecific PET/CT manifestations, representing preliminary yet inconclusive differentiation value. Several features, including FDG distribution patterns and lesion morphology, correlate with treatment response, but their causal relationship remains undetermined. Pleural involvement in PPL is associated with improved treatment response, while elevated baseline TBR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.